Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity

Open access
Košak, Urban, Brus, Boris, Knez, Damijan, Žakelj, Simon, Trontelj, Jurij, Pišlar, Anja, Šink, Roman, Jukič, Marko, Živin, Marko, Podkowa, Adrian, Nachon, Florian, Brazzolotto, Xavier, Stojan, Jure, Kos, Janko, Coquelle, Nicolas, Sałat, Kinga, Colletier, Jacques-Philippe, Gobec, Stanislav·2018·Journal of Medicinal Chemistry

Abstract

The enzymatic activity of butyrylcholinesterase (BChE) in the brain increases with the progression of Alzheimer's disease, thus classifying BChE as a promising drug target in advanced Alzheimer's disease. We used structure-based drug discovery approaches to develop potent, selective, and reversible human BChE inhibitors. The most potent, compound 3, had a picomolar inhibition constant versus BChE due to strong cation-π interactions, as revealed by the solved crystal structure of its complex with human BChE. Additionally, compound 3 inhibits BChE ex vivo and is noncytotoxic. In vitro pharmacokinetic experiments show that compound 3 is highly protein bound, highly permeable, and metabolically stable. Finally, compound 3 crosses the blood-brain barrier, and it improves memory, cognitive functions, and learning abilities of mice in a scopolamine model of dementia. Compound 3 is thus a promising advanced lead compound for the development of drugs for alleviating symptoms of cholinergic hypofunction in patients with advanced Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.7b01086

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 160

Metadata

Authors
Košak, U., Brus, B., Knez, D., Žakelj, S., Trontelj, J., Pišlar, A., Šink, R., Jukič, M., Živin, M., Podkowa, A., Nachon, F., Brazzolotto, X., Stojan, J., Kos, J., Coquelle, N., Sałat, K., Colletier, J.-P., & Gobec, S.
Venue
Journal of Medicinal Chemistry
Published
2017-12-22
Volume
61
Issue
1
Pages
119-139
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2773982889
Cited by
160
References
8
FWCI
8.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity. https://app.cochat.ai/papers/10.1021/acs.jmedchem.7b01086
The paper
Košak, U., Brus, B., Knez, D., Žakelj, S., Trontelj, J., Pišlar, A., Šink, R., Jukič, M., Živin, M., Podkowa, A., Nachon, F., Brazzolotto, X., Stojan, J., Kos, J., Coquelle, N., Sałat, K., Colletier, J.-P., & Gobec, S. (2018). The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.7b01086

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.